-
-
-
-
-
-
-
Genmab (GMAB) Announces That AbbVie (ABBV) Will Submit MAA to EMA for Epcoritamab for the Treatment of R/R DLBCL
-
-
-
-
-
-
-
AbbVie Submits Applications for Upadacitinib (RINVOQ®) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)
-
-
-
-
-
-
-
AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
-
-
-
-
-
-
-
Form 4 AbbVie Inc. For: Sep 30 Filed by: Alpern Robert J
-
-
-
-
-
-
-
AbbVie to Acquire Allergan in Transformative Move for Both Companies
-
-
-
-
-
-
-
Enanta Pharma (ENTA) Affirms FDA Breakthrough Therapy Designation Given to AbbVie’s HCV Regimen
-
-
-
-
-
-
-
Pre-Open Stock Movers 01/08: (BIND) (BIOD) (AVEO) Higher; (INFI) (PODD) (ARNA) Lower (more...)
55,438 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All